Clinical practice interviews - Polish Archives of Internal Medicine

Treatment of hypertension: When to start? What is the target? Dr. Franz H. Messerli in an interview with Dr. Roman Jaeschke: part 2

Franz H. Messerli, Roman Jaeschke

Pol Arch Intern Med. 2017, Vol. 127, No. 3: 221–222; DOI: 10.20452/pamw.3993

Treatment of hypertension: choosing the first‑line treatment. Dr. Franz H. Messerli in an interview with Dr. Roman Jaeschke: part 1

Franz H. Messerli, Roman Jaeschke

Pol Arch Intern Med. 2017, Vol. 127, No. 3: 219–220; DOI: 10.20452/pamw.3992

Microbiome: fecal transplant in Clostridium difficile and ulcerative colitis. Dr. Paul Moayyedi in an interview with Dr. Roman Jaeschke: part 2

Paul Moayyedi, Roman Jaeschke

Pol Arch Intern Med. 2017, Vol. 127, No. 2: 137–138; DOI: 10.20452/pamw.3963

Microbiome: the beginning of understanding. Dr. Paul Moayyedi in an interview with Dr. Roman Jaeschke: part 1

Paul Moayyedi, Roman Jaeschke

Pol Arch Intern Med. 2017, Vol. 127, No. 2: 135–136; DOI: 10.20452/pamw.3961

Cystic fibrosis: past, present, future. Dr. Andreas Freitag in an interview with Dr. Roman Jaeschke

Andreas Freitag, Roman Jaeschke

Pol Arch Intern Med. 2017, Vol. 127, No. 1: 73–75; DOI: 10.20452/pamw.3922

HOPE‑3, BP treatment, milestones in CV prevention. Dr. Salim Yusuf in an interview with Dr. Akbar Panju and Dr. Roman Jaeschke

Salim Yusuf, Akbar Panju, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 12: 1033–1035; DOI: 10.20452/pamw.3765

Treatment of asthma: predicting the future of atopic disease treatment Dr. Paul O’Byrne in an interview with Dr. Roman Jaeschke: part 2

Paul O’Byrne, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 12: 1031–1032; DOI: 10.20452/pamw.3763

Treatment of asthma: roles of different classes of drugs Dr. Paul O’Byrne in an interview with Dr. Roman Jaeschke: part 1

Paul O’Byrne, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 12: 1028–1030; DOI: 10.20452/pamw.3761

VTE treatment in 201 6 and future challenges Dr. Mark Crowther in an interview with Dr. Roman Jaeschke: part 3

Mark Crowther, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 12: 1026–1027; DOI: 10.20452/pamw.3780

Milestones in VTE treatment. Dr. Mark Crowther in an interview with Dr. Roman Jaeschke: part 2

Mark Crowther, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 12: 1025–1025; DOI: 10.20452/pamw.3778

2015 in hematology and thromboembolism. Dr. Mark Crowther in an interview with Dr. Roman Jaeschke: part 1

Mark Crowther, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 12: 1024–1024; DOI: 10.20452/pamw.3776

Safety of long‑acting ß2‑agonists: current state of knowledge. Dr. Paul O’Byrne in an interview with Dr. Roman Jaeschke: part 2

Paul O’Byrne, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 11: 912–913; DOI: 10.20452/pamw.3669

Safety of long‑acting β2‑agonists: a little bit of history. Dr. Paul O’Byrne in an interview with Dr. Roman Jaeschke: part 1

Paul O’Byrne, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 11: 910–911; DOI: 10.20452/pamw.3667

Aspirin in prevention of cardiovascular events. Dr. Gordon Guyatt in an interview with Dr. Roman Jaeschke

Gordon Guyatt, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 11: 909–909; DOI: 10.20452/pamw.3665

Drugs in diabetes in 2016, changes in endocrinology in 2015. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke

Hertzel Gerstein, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 11: 907–908; DOI: 10.20452/pamw.3663

Stress ulcer prophylaxis in critical care: a 2016 perspective Dr. Waleed Alhazzani in an interview with Dr. Roman Jaeschke: part 2

Waleed Alhazzani, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 10: 796–797; DOI: 10.20452/pamw.3606

SPRINT trial and blood pressure treatment. Dr. Gordon Guyatt in an interview with Dr. Roman Jaeschke

Gordon Guyatt, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 10: 806–807; DOI: 10.20452/pamw.3614

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke

Hertzel Gerstein, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 10: 803–805; DOI: 10.20452/pamw.3612

Periprocedural risk of bleeding and thrombosis: to bridge or not to bridge. Dr. James Douketis in an interview with Dr. Roman Jaeschke: part 2

James Douketis, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 10: 801–802; DOI: 10.20452/pamw.3610

BRIDGE trial. Dr. James Douketis in an interview with Dr. Roman Jaeschke: part 1

James Douketis, Roman Jaeschke

Pol Arch Intern Med. 2016, Vol. 126, No. 10: 798–800; DOI: 10.20452/pamw.3608